PP
EVGN icon

PDT Partners’s Evogene EVGN Stock Holding History

PDT Partners’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,740
Closed -$204K – 910
2021
Q3 		$204K Sell
7,740
-8,882
-53% -$259K 0.01% 690
2021
Q2 		$568K Sell
16,622
-1,929
-10% -$75.6K 0.04% 489
2021
Q1 		$935K Buy
18,551
+10,352
+126% +$641K 0.07% 385
2020
Q4 		$385K Buy
+8,199
New +$289K 0.03% 499

Other funds holding EVGN

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EVC
Eidelman Virant Capital Saint Louis, Missouri $136M AUM 15.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PDT Partners's EVGN Position: Q4 2021 in Review

PDT Partners sold out of Evogene (EVGN) in Q4 2021, closing a stake of 7,740 shares — an estimated $204K sold.

PDT Partners first reported a position in EVGN in Q4 2020 and held it in 4 quarters. The position peaked at $935K in Q1 2021. 42 funds tracked by Wall St. Rank hold EVGN as of Q4 2021.

  • PDT Partners reported no remaining Evogene position as of Q4 2021 after selling out during the quarter.
  • PDT Partners sold 7,740 Evogene shares in Q4 2021, an estimated $204K.
  • PDT Partners first reported a position in Evogene in Q4 2020 and held it in 4 quarters.
  • PDT Partners's Evogene position peaked at $935K in Q1 2021.
  • 42 funds tracked by Wall St. Rank held Evogene as of Q4 2021.

Based on PDT Partners's 13F filing for Q4 2021, filed 14 Feb 2022.